Fe nwick & West represented Dermira, Inc. (NAS: DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, in its underwritten public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock, for estimated net proceeds to Dermira of approximately $135.8 million. The offering was made pursuant to an effective shelf registration statement on Form S-3 that Dermira previously filed with the SEC.
Leerink Partners, Cowen and Company and Guggenheim Securities acted as joint book-running managers for the offering. Needham and Company acted as co-manager.
The Fenwick transaction team included corporate partner Michael Brown and associates Katherine Duncan, Jennifer Hitchcock, Can Sun and Jeremy Kazzaz.